Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Daptics was a machine learning-guided protein engineering company that developed a proprietary "Smart Design of Experiments" (Smart DOE) platform. The technology was designed to optimize protein sequences and experimental workflows, allowing for more efficient discovery and refinement of biological molecules. By utilizing advanced algorithms, Daptics helped researchers navigate complex sequence spaces to identify optimal protein variants with significantly fewer experimental iterations. The company was acquired by Ginkgo Bioworks in October 2021 to integrate its AI-driven optimization tools into Ginkgo's horizontal cell programming platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Daptics.